An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.

EBioMedicine · 2019 · PMC6945285 · PMID 31668570

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, due to the limited number of available KRAS(G12C) mutant tumours, this correlation did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.